Drugs, Pregnancy & Lactation

Breastfeeding with the FDA’s novel drugs approved in 2017, and others


 

Gastrointestinal

Plecanatide (Trulance) (MW 1.7 kg/mol). Diarrhea.

Telotristat (Xermelo) (MW 574 g/mol). Nausea, headache, increased gamma-glutamyltransferase, depression, flatulence, decreased appetite, peripheral edema, pyrexia.

Hematologic

Betrixaban (Bevyxxa) (MW 568 g/mol). Bleeding.

Emicizumab (Hemlibra) (MW 145.6 kg/mol). Headache, arthralgia.

Immunologic

Sarilumab (Kevzara) (MW 150 kg/mol). Neutropenia, increased ALT, upper respiratory infections, urinary tract infections.

Ophthalmic

Latanoprostene bunod (Vyzulta) (MW 508 g/mol). All related to the eye.

Netarsudil (Rhopressa) (MW 454 g/mol). All related to the eye.

Parathyroid hormone

Abaloparatide (Tymlos) (MW 3.9 kg/mol). Hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain, vertigo.

Respiratory

Benralizumab (Fasenra) (MW 150 kg/mol). Headache, pharyngitis.

Pages

Next Article: